Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levofloxacin vs Piperacillin/Tazobactam in Hospital-Acquired Pneumonia
NCT00253955Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2003
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial of levofloxacin in hospital-acquired pneumonia (HAP) (2 arms), sponsored by Sanofi. Primary endpoint: Clinical Efficacy at Test of Cure. Started Jun 2003; status: completed.
02
Drugs
levofloxacin
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on NCT00253955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00253955.